These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7038206)

  • 21. Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
    Dabich L; Bull FE; Beltran G; Athens JW; Coltman CA; Weick JK; Van Slyck EJ; Amare M
    Cancer Treat Rep; 1986 Aug; 70(8):967-9. PubMed ID: 3460700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Aclarubicin in metastatic thyroid cancer: initial clinical experience].
    Langsteger W; Lind P; Eber O; Költringer P; Klima G
    Radiobiol Radiother (Berl); 1988; 29(2):243-5. PubMed ID: 3165198
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of acute non-lymphocytic leukemia in Saitama Cancer Center.
    Sampi K; Sakurai M; Kaneko Y; Hattori M
    Anticancer Res; 1985; 5(3):293-6. PubMed ID: 4015043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of clinical studies on aclacinomycin A--phase I and preliminary phase II evaluation of ACM.
    Oka S
    Sci Rep Res Inst Tohoku Univ Med; 1978 Dec; 25(3-4):37-49. PubMed ID: 572582
    [No Abstract]   [Full Text] [Related]  

  • 25. [Therapy of acute leukemia: contribution of the new anthracyclinic drugs].
    Lambertenghi-Deliliers G; Colajori E; Annaloro C; Polli EE
    Recenti Prog Med; 1985; 76(7-8):392-7. PubMed ID: 3906794
    [No Abstract]   [Full Text] [Related]  

  • 26. Future clinical investigations with anthracycline antibiotics in relation to daunorubicin.
    Muggia FM; Blum RH; Wernz JC
    Cancer Treat Rep; 1981; 65 Suppl 4():35-7. PubMed ID: 6955012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aclacinomycin A.
    Oka S; Mathé G; Mitrou PS
    Cancer Treat Rev; 1984 Dec; 11(4):299-302. PubMed ID: 6598408
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
    Warrell RP; Arlin ZA; Kempin SJ; Young CW
    Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aclarubicin in the treatment of multiple myeloma.
    Sezaki T; Adachi T; Ishii H; Asano K; Takahashi I; Kimura I
    Jpn J Clin Oncol; 1984 Sep; 14(3):353-8. PubMed ID: 6384577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aclarubicin: a new drug in cancer treatment. Proceedings of a satellite symposium. June 17th, 1985, Stockholm.
    Eur J Haematol Suppl; 1987; 47():1-76. PubMed ID: 3471522
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase II study of aclarubicin in previously untreated patients with advanced soft tissue sarcoma: a Southeastern Cancer Study Group trial.
    Bertrand M; Multhauf P; Bartolucci A; Ellison D; Gockerman J
    Cancer Treat Rep; 1985 Jun; 69(6):725-6. PubMed ID: 3860295
    [No Abstract]   [Full Text] [Related]  

  • 32. [Experiences in the treatment of immature cell leukemias with cytosine arabinoside and daunorubidomycin].
    Schmalzl F; Braunsteiner H
    Wien Klin Wochenschr; 1971 Jun; 83(25):452-6. PubMed ID: 5289111
    [No Abstract]   [Full Text] [Related]  

  • 33. [Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
    Takahashi I; Hara M; Ohmoto E; Oda Y; Endo Y; Fujimoto S; Uchida K; Takaoka K; Watanabe S; Lai M; Kohi F; Kitajima K; Kimura I; Sanada H; Tokioka M; Adachi T; Yorimitsu S
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1617-22. PubMed ID: 6964050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aclacinomycin A: clinical development of a novel anthracycline antibiotic in the haematological cancers.
    Warrell RP
    Drugs Exp Clin Res; 1986; 12(1-3):275-82. PubMed ID: 3525076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II evaluation of aclarubicin in advanced breast cancer: a Southeastern Cancer Study Group trial.
    Gockerman JP; Raney M; Logan T
    Cancer Treat Rep; 1985 Sep; 69(9):1029-30. PubMed ID: 3861247
    [No Abstract]   [Full Text] [Related]  

  • 36. [Aclacinomycin-A in acute leukaemias and leukaemic non-Hodgkin lymphomas (author's transl)].
    Mathé G; de Jager R; Hulhoven R; Delgado M; Machover D; Ribaud P; de Vassal F; Gil-Delgado M; Misset JL; Gouveia J; Jasmin C; Hayat M; Gastiaburu J; Schwarzenberg L
    Nouv Presse Med; 1982 Jan; 11(1):25-8. PubMed ID: 6949137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Aclacinomycin A and behenoyl ara-C combination chemotherapy for untreated acute non-lymphocytic leukemia].
    Sampi K; Honda T; Hayashi Y; Hattori M
    Gan To Kagaku Ryoho; 1983 Oct; 10(10):2211-6. PubMed ID: 6578705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aclarubicin in single agent and combined chemotherapy of acute myeloid leukaemias.
    Mitrou PS
    Eur J Haematol Suppl; 1987; 47():59-66. PubMed ID: 3471526
    [No Abstract]   [Full Text] [Related]  

  • 39. Aclarubicin in the treatment of relapsed or resistant acute myelogenous leukaemia: a phase II trial.
    Evensen SA; Wisløff F; Müller E; Talstad I; Waage A; Johansen L
    Eur J Haematol Suppl; 1987; 47():43-7. PubMed ID: 3471524
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase I-II study of aclarubicin for treatment of acute myeloid leukaemia.
    Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Benavides M; Lotz JP; Misset JL; de Vassal F; Tapiero H
    Eur J Haematol Suppl; 1987; 47():33-42. PubMed ID: 3471523
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.